2,5-Hexanedione-induced changes in the monomeric neurofilament protein content of rat spinal cord fractions.
Quantitative morphometric analyses have demonstrated that axon atrophy is the primary neuropathic feature in the CNS and PNS of rats intoxicated with 2,5-hexanedione (HD). Axon caliber is maintained by the exchange of mobile neurofilament (NF) subunits with the stationary polymer and, therefore, HD might produce atrophy by disrupting cytoskeletal turnover. To evaluate this possibility, groups of rats were exposed to HD at dosing schedules (175 mg/kg x 101 days or 400 mg/kg x 26 days) that produced moderate levels of neurological deficits and prevalent axon atrophy in spinal cord white matter tracts. Lumbar spinal cord regions from HD-intoxicated rats and their age-matched controls were Triton-extracted and separated by differential fractionation into a low-speed, insoluble pellet (P1) of NF polymer and a high-speed supernatant fraction (S2), which presumably contained mobile monomer. Cytoskeletal protein contents (NF-L, -M, -H, and beta-tubulin) in each fraction were determined by immunoblot analysis. Results show that regardless of HD dose-rate, the NF polymer in P1 remained unaffected, although soluble monomer in the S2 fraction was depleted significantly (60-80% reduction). Fractional beta-tubulin contents were inconsistently affected and abnormal higher-molecular-weight NF proteins were detected in the P1 fraction only. Studies with antibodies directed against phosphorylated (RT97) and nonphosphorylated (SMI32) epitopes on NF-H and measurements of corresponding isoelectric range suggested that alterations in phosphorylation were not involved. The selective depletion of Triton-soluble protein suggested that HD adduction of NFs interfered with the dynamic interactions of the polymeric and mobile monomeric pools.
LoPachin
Richard M
RM
Department of Anesthesiology, Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, NY 10467, USA. lopachin@aecom.yu.edu
He
Deke
D
Reid
Maria L
ML
Opanashuk
Lisa A
LA
D000284:Administration, Oral; D000818:Animals; D001284:Atrophy; D001369:Axons / Q000187:drug effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D006588:Hexanones / Q000008:administration & dosage / Q000633:toxicity*; D008161:Lumbosacral Region; D008297:Male; D009410:Nerve Degeneration / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology; D016900:Neurofilament Proteins / Q000187:drug effects* / Q000378:metabolism; D020258:Neurotoxicity Syndromes; D009498:Neurotoxins / Q000008:administration & dosage / Q000633:toxicity*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013116:Spinal Cord / Q000187:drug effects* / Q000378:metabolism; D013118:Spinal Cord Diseases / Q000139:chemically induced* / Q000378:metabolism / Q000503:physiopathology; D013347:Subcellular Fractions
D006588:Hexanones; D016900:Neurofilament Proteins; D009498:Neurotoxins; C011269:2,5-hexanedione